ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01672 ASCLETIS-B

Trading 02-11 14:09:44

17.070

-0.070

-0.41%

High18.640	Low17.000	Vol6.35M
Open17.730	D1 Closing17.140	Amplitude9.57%
Mkt Cap18.11B	Tradable Cap18.11B	Total Shares1.06B
T/O113.34M	T/O Rate0.60%	Tradable Shares1.06B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"ASCLETIS-B","latestPrice":17.07,"timestamp":1770790177829,"preClose":17.14,"halted":0,"volume":6353000,"delay":0,"changeRate":-0.004084014002333739,"floatShares":1061000000,"shares":1061000000,"eps":-0.33990624645801587,"marketStatus":"Trading","change":-0.07,"latestTime":"02-11 14:09:44","open":17.73,"high":18.64,"low":17,"amount":113340461,"amplitude":0.095683,"askPrice":17.13,"askSize":5000,"bidPrice":17.05,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.30012656562341267,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770797400000},"marketStatusCode":2,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":17.14,"openAndCloseTimeList":[[1770773400000,1770782400000],[1770786000000,1770796800000]],"volumeRatio":2.011414,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672/wiki","defaultTab":"wiki","newsList":[{"id":"2610605904","title":"Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2610605904","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610605904?lang=en_us&edition=fundamental","pubTime":"2026-02-11 09:49","pubTimestamp":1770774544,"startTime":"0","endTime":"0","summary":"Ascletis Pharma  said it had selected a once-daily version of the ASC37 oral tablets for further studies in the US, according to a Hong Kong bourse filing Wednesday.The company plans to seek U.S. regulatory approval to begin human trials of the oral version of the drug to treat obesity.An investigational new drug application is expected in the second quarter of 2026, the firm said.According to Ascletis, animal studies showed its medicine was superior to eloralintide and petrelintide.The company is also advancing a once-monthly subcutaneous version of ASC37.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","01672","BK1515","BK1574"],"gpt_icon":0},{"id":"2610605531","title":"BRIEF-Ascletis Pharma Selects Asc36 For Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2610605531","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610605531?lang=en_us&edition=fundamental","pubTime":"2026-02-11 09:39","pubTimestamp":1770773966,"startTime":"0","endTime":"0","summary":"BRIEF-Ascletis Pharma Selects Asc36 For Clinical DevelopmentFeb 11 (Reuters) - Ascletis Pharma Inc 1672.HK:SELECTS ASC36 FOR CLINICAL DEVELOPMENTFurther company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z61PA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1574","BK1515","BK1161"],"gpt_icon":0},{"id":"2610495677","title":"Ascletis Pharma: Expects to Submit Ind to FDA for Asc36 Oral Tablets for Treatment of Obesity in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610495677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610495677?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:33","pubTimestamp":1770766415,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z61PD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1515","BK1574","01672"],"gpt_icon":0},{"id":"1119175533","title":"Ascletis Pharma Inc. (1672) Announces Oral Amylin Receptor Peptide Agonist ASC36 for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1119175533","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119175533?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:21","pubTimestamp":1770765699,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. (1672) announced the selection of its first oral amylin receptor peptide agonist, ASC36, for clinical development. The company plans to submit an Investigational New Drug...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"gpt_icon":0},{"id":"1184933773","title":"ASCLETIS-B Selects Oral Amylin Receptor Agonist Peptide ASC36 for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1184933773","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184933773?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:10","pubTimestamp":1770765027,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced that its Board of Directors has selected its first oral amylin receptor agonist peptide, ASC36 oral tablets, for clinical development. The company anticipates submitting...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1191","01477","BK1515","01672"],"gpt_icon":0},{"id":"2610672245","title":"Ascletis Pharma Inc - Selects Asc36 for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2610672245","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610672245?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:01","pubTimestamp":1770764467,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z61PA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","01672","BK1574"],"gpt_icon":0},{"id":"2610221672","title":"Ascletis Pharma Selects Oral Amylin Agonist ASC36 for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2610221672","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610221672?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:00","pubTimestamp":1770764458,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has announced the selection of ASC36, its first oral amylin receptor peptide agonist, for clinical development. ASC36 oral tablets were developed using the company's proprietary Peptide Oral Transport ENhancement Technology . In non-human primate studies, the tablets achieved an absolute oral bioavailability of 6% to 8% at steady state. Ascletis plans to submit an Investigational New Drug Application  to the U.S. Food and Drug Administration  for ASC36 oral tablets for the treatment of obesity in the second quarter of 2026. No clinical study results have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL7GCS3J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","01672","BK1161"],"gpt_icon":0},{"id":"1131639772","title":"Ascletis Pharma (01672) Announces 69.256 Million New Shares Issued and Provides Share Repurchase Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1131639772","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131639772?lang=en_us&edition=fundamental","pubTime":"2026-02-10 18:24","pubTimestamp":1770719053,"startTime":"0","endTime":"0","summary":"On 10 February 2026, Ascletis Pharma Inc. announced the placement of 69,256,000 new ordinary shares under a general mandate at HKD 12.18 per share. This issuance represents 6.98% of the existing...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"gpt_icon":0},{"id":"1197995711","title":"Ascletis Pharma (1672) Announces Completion of New Share Placement Under General Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1197995711","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197995711?lang=en_us&edition=fundamental","pubTime":"2026-02-10 17:45","pubTimestamp":1770716736,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. (1672) completed the placing of 69,256,000 new shares at HK$12.18 per share on February 10, 2026. The transaction raised gross proceeds of approximately HK$843.5 million, while...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"gpt_icon":0},{"id":"1173013510","title":"ASCLETIS-B Completes Placement of 69.256 Million Shares, Raising Approximately HK$835 Million Net Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=1173013510","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173013510?lang=en_us&edition=fundamental","pubTime":"2026-02-10 17:44","pubTimestamp":1770716683,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) has announced the successful completion of a placement involving a total of 69.256 million shares on February 10, 2026. The shares were priced at HK$12.18 per share, generating net...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01477","BK1191","BK1515","01672","BK1161"],"gpt_icon":0},{"id":"2610484996","title":"Ascletis Pharma platziert 69,26 Millionen neue Aktien bei Investoren","url":"https://stock-news.laohu8.com/highlight/detail?id=2610484996","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610484996?lang=en_us&edition=fundamental","pubTime":"2026-02-10 17:30","pubTimestamp":1770715840,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. hat den Abschluss einer Privatplatzierung bekanntgegeben. Im Rahmen der Transaktion wurden rund 69 Millionen neue Aktien zu einem Preis von 12,18 HK-Dollar je Aktie an mindestens sechs Investoren ausgegeben. Die Platzierung erfolgte unter Ausschluss des ffentlichen Angebots und ohne Registrierung in den USA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL3Dtg6v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","01672","BK1574"],"gpt_icon":0},{"id":"1151906748","title":"ASCLETIS-B (01672) Rises Over 6% Again as ASC30 Accelerates Global Phase III Trials; Analysts See High BD Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1151906748","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151906748?lang=en_us&edition=fundamental","pubTime":"2026-02-10 14:54","pubTimestamp":1770706461,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) climbed more than 6% in Hong Kong trading, extending recent gains. At the time of writing, the stock was up 5.52% to HK$17.2, with a turnover of HK$69.458 million. The rally...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4588","BK1515","01477","III","VT","01672","BK1191","BK4134","BK4585","BK1574","VXUS"],"gpt_icon":0},{"id":"1193757120","title":"HK Movers | HK's Biotech Shares Soar. ImmuneOnco up 7%; Zai Lab, Remegen, Innovent Bio up 5%; Ascletis, Wuxi Bio up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193757120","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193757120?lang=en_us&edition=fundamental","pubTime":"2026-02-10 10:11","pubTimestamp":1770689475,"startTime":"0","endTime":"0","summary":"Hong Kong’s biotech stocks rose on Tuesday.ImmuneOnco up 7%; Zai Lab, Remegen, Innovent Bio up 5%; Ascletis, Wuxi Bio up 4%; AKESO up 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","09688","01541"],"gpt_icon":0},{"id":"1148180037","title":"HK Movers | Ascletis Pharma Stock up 8% After GIC Invests US$100M in Company, Anchoring Long-Term Capital in China's Core Innovative Drug Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=1148180037","media":"Tiger Newspress","labels":["shareholding","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148180037?lang=en_us&edition=fundamental","pubTime":"2026-02-09 10:12","pubTimestamp":1770603160,"startTime":"0","endTime":"0","summary":"According to disclosure of interests filed with the Hong Kong Stock Exchange (HKEX), the Government of Singapore Investment Corporation (GIC) has acquired an initial stake in Ascletis Pharma (1672....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5b8e836eb28e93182c6665cd3882a9d1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"HK Movers | Ascletis Pharma Stock up 8% After GIC Invests US$100M in Company, Anchoring Long-Term...","news_tag":"shareholding,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"gpt_icon":0},{"id":"1159339612","title":"ASCLETIS-B Shares Surge Nearly 9% in Morning Session Following GIC's HK$781 Million Stake Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=1159339612","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159339612?lang=en_us&edition=fundamental","pubTime":"2026-02-09 09:46","pubTimestamp":1770601588,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) rose nearly 9% during the morning trading session. At the time of writing, the stock was up 8.29%, trading at HK$16.46, with a turnover of HK$14.289 million. The price movement...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5b8e836eb28e93182c6665cd3882a9d1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","VXUS","01672","BK1191","VT","BK1574","01477","BK4585","BK4588","GIC","BK4104","BK1161"],"gpt_icon":0},{"id":"1197290640","title":"Tirzepatide Crowned as New \"Blockbuster Drug King\" with Rapid Commercial Value Release Expected for Weight Loss Medications","url":"https://stock-news.laohu8.com/highlight/detail?id=1197290640","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197290640?lang=en_us&edition=fundamental","pubTime":"2026-02-05 13:54","pubTimestamp":1770270882,"startTime":"0","endTime":"0","summary":"Orient Securities has released a research report stating that, according to Eli Lilly's disclosed 2025 performance, Tirzepatide achieved annual sales of $36.507 billion, representing a 122% increase....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1564","BK1147","LU0067412154.USD","01672","LU0072913022.USD","LU1807302812.USD","LU1226288253.USD","LU1993786604.SGD","BK1191","BK1515","IE0008369823.USD","IE00B031HY20.USD","LU1960683339.HKD","BK1521","LU0314109678.HKD","BK0028","BK0276","BK0012","IE00BZ08YR35.GBP","LU0326950275.SGD","LU1152091168.USD","LU1008478684.HKD","LU1226287792.SGD","600958","IE00B543WZ88.USD","LU1226287875.USD","LU0880133367.SGD","01093","BK0183","IE0008368742.USD","LU2039709279.SGD","BK0188","LU0315179316.USD","LU1226287529.USD","IE00BZ08YS42.EUR","LU1328277881.USD","LU1951186391.HKD","IE00BZ08YT58.USD","SG9999004220.SGD","HK0000165453.HKD","BK1574","LU0501845795.SGD","IE00B5MMRT66.SGD","LU1813983027.USD","BK1161","LU1226288170.HKD","03958","LU1152091754.HKD","LU0140636845.USD"],"gpt_icon":0},{"id":"2608594395","title":"Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2608594395","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608594395?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:31","pubTimestamp":1770215473,"startTime":"0","endTime":"0","summary":"Ascletis Pharma recently filed a follow-on equity offering of HK$843.54 million via a subsequent direct listing, issuing 69,256,000 ordinary shares at HK$12.18 each.\nThe fundraising follows positive Phase III data for denifanstat in moderate-to-severe acne and progress with ASC30 in metabolic disease, underscoring Ascletis’s late-stage pipeline momentum.\nWe’ll now explore how this combination of positive Phase III acne data and a sizable equity raise shapes Ascletis Pharma’s investment...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/ascletis-pharma-sehk1672-is-up-54-after-hk844m-follow-on-off","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/ascletis-pharma-sehk1672-is-up-54-after-hk844m-follow-on-off","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4134","III","01672","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"2608807643","title":"After Clearing Up Acne, Sagimet Stock Rises -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2608807643","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608807643?lang=en_us&edition=fundamental","pubTime":"2026-02-04 04:27","pubTimestamp":1770150420,"startTime":"0","endTime":"0","summary":"Shares of Sagimet Biosciences were up as much as 12% Tuesday morning, on encouraging clinical trial results for its acne treatment and a new Buy recommendation from Guggenheim Securities.For much of its history, the San Mateo, Calif-based firm played up the promise of its novel drug for treating liver diseases brought on by obesity. But lately, it is drawing attention for those drugs' success at clearing a more familiar affliction: acne.The news helped lift Sagimet stock Tuesday to $7.20 and bring the little company's market cap to $230 million. That is well below the $16 level where Sagimet came public in 2023. But in a Tuesday note launching coverage on the company, Guggenheim's Seamus Fernandez says the stock can rise as high as $27, if either the liver or acne drug reach his expectations.If approved and launched by 2030, he thinks the drug's sales as a first line treatment for acne could surpass a billion dollars. The existing treatments include generic versions of the Roche drug A","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01672","BK1515","BK4139","SGMT","BK1161"],"gpt_icon":0},{"id":"1136207146","title":"Ascletis (01672) Publishes Monthly Return on Securities Movements for January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1136207146","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136207146?lang=en_us&edition=fundamental","pubTime":"2026-02-03 19:25","pubTimestamp":1770117954,"startTime":"0","endTime":"0","summary":"On 3 February 2026, Ascletis Pharma Inc. (stock code: 01672) released its Monthly Return for Equity Issuer for the period ended 31 January 2026. The authorized share capital remained at 7,000,000,000...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"gpt_icon":0},{"id":"2608123118","title":"Ascletis Pharma Seeks HK$843 Million via Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2608123118","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608123118?lang=en_us&edition=fundamental","pubTime":"2026-02-03 09:20","pubTimestamp":1770081645,"startTime":"0","endTime":"0","summary":"Ascletis Pharma  said it was looking to raise HK$843.5 million via a share offering, according to a Hong Kong bourse filing Tuesday.The firm is seeking investors for around 69.3 million shares priced at HK$12.18 apiece to raise funds for the global phase 3 trials of its ASC30 drug for the treatment of obesity.The shares represent 6.98% of the company's issued share capital.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1515","BK1574","01672"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":0.3104},{"period":"1month","weight":0.3614},{"period":"3month","weight":0.5195},{"period":"6month","weight":0.0987},{"period":"1year","weight":3.0425},{"period":"ytd","weight":0.5048}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.0097},{"period":"6month","weight":0.0652},{"period":"1year","weight":0.263},{"period":"ytd","weight":0.0606}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.112559},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.058802},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.059274},{"month":5,"riseRate":0.428571,"avgChangeRate":0.007612},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.024499},{"month":7,"riseRate":0.571429,"avgChangeRate":0.032162},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.037953},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"ASCLETIS-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ASCLETIS-B(01672) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ASCLETIS-B,01672,ASCLETIS-B股票,ASCLETIS-B股票老虎,ASCLETIS-B股票老虎国际,ASCLETIS-B行情,ASCLETIS-B股票行情,ASCLETIS-B股价,ASCLETIS-B股市,ASCLETIS-B股票价格,ASCLETIS-B股票交易,ASCLETIS-B股票购买,ASCLETIS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ASCLETIS-B(01672),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ASCLETIS-B(01672) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}